Study: Hearing, visually impaired adults less likely to be vaccinated for COVID-19

Article

A recent study shows US adults with hearing and visual impairments have lower rates of vaccination for the coronavirus.

A recent cross-sectional study1 shows that COVID-19 vaccination rates are lower among individuals with hearing and visual impairments, compared to those without.

Reported by Kea Turner, PhD, MPH, MA, from the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, and colleagues, the studyincluded adults who participated in the US Census Bureau Household Pulse Survey from April 2021 through March 2022.

The survey collected data on acquisition of the COVID-19 vaccine and determinants of health care access, including demographic and clinical characteristics, as well as social determinants of health, Turner described.

The primary outcome measure was the first COVID-19 vaccine.

The participating patients had difficulty seeing or hearing despite corrective measures or they were blind or deaf.

Assessment of impaired adults

The study included 916, 085 adults (mean age, 54.0 years; 52.0% women), most of whom (82.7%) started the COVID-19 vaccine series.

Compared with adults who were not visually impaired, those with serious visual impairment (mean difference, −6.3%, p <0 .001) and blindness (mean difference, −20.1%, p < 0.001) had lower COVID-19 vaccination rates.

Compared with adults who were not hearing impaired or deaf, adults with serious hearing impairment (mean difference, −2.1%; p =0 .003) and deafness (mean difference, −17.7%, p < 0.001) were less likely to start the COVID-19 vaccine process.

The adults who were the most seriously affected, i.e., those who were blind (p=0.009) or deaf (p=0.003), were less likely to start the series of vaccinations compared with those who were less visually or hearing impaired, respectively.

“The findings of this study suggest that COVID-19 vaccine initiation is lower among adults with vision or hearing disabilities compared with adults without disabilities; this information may inform initiatives to promote equitable and accessible vaccination. Additional research may be needed to monitor COVID-19 vaccination disparities among adults with vision or hearing disabilities and to address disparities,” the investigators concluded.

Reference
1. Turner K, Nguyen OT, Alishahi AM, et al. COVID-19 vaccination rates among US adults with vision or hearing disabilities. JAMA Ophthalmol. Published online August 11, 2022; doi:10.1001/jamaophthalmol.2022.3041

Recent Videos
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
© 2025 MJH Life Sciences

All rights reserved.